First-in-human phase 1/2 dose escalation and expansion study evaluating first-in-class eIF4A inhibitor zotatifin in patients with solid tumors Meeting Abstract
| Authors: | Meric-Bernstam, F.; Sharma, M.; Sommerhalder, D.; Skeel, R. T.; El-Khoueiry, A. B.; Caswell-Jin, J. L.; Patel, P. H.; Rosen, E. |
| Abstract Title: | First-in-human phase 1/2 dose escalation and expansion study evaluating first-in-class eIF4A inhibitor zotatifin in patients with solid tumors |
| Meeting Title: | 2022 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 40 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2022 Jun 3-7 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2022-06-01 |
| Language: | English |
| ACCESSION: | WOS:000863680300974 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2022.40.16_suppl.3081 |
| Notes: | Meeting Abstract: 3081 -- Meeting also held virtually -- Source: Wos |
